Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“The hypothesis first proposed by Thomas and Burnet in the 1970s implied that the immune response to tumor occurred at an early stage in tumor development—‘‘eradicating the cancer before it became apparent’’ [13, 14].”
BackgroundTolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820 · cited 1×
“Similar observations were also reported by our group where immunization with irradiated RENCA cells (murine renal carcinoma) infected with DISC-HSV (disabled infectious single cycle–herpes simplex virus) that enhanced immunity to tumor challenge with live parental tumor cells that induced cell death by necrosis as opp…”
ResultInhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563 · cited 1×
“The caspase-8 inhibitor, cellular FLICE-inhibitory protein (cFLIP), is expressed in many tumors making them resistant to death receptor–mediated apoptosis [30].”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 2×
“mouse tumor cells prevents their rejection in preimmunized mice, correlating with the lack of specific T-cell accumulation at the tumor site [43].”
BackgroundThe TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887 · cited 1×
“Members of the TNFR superfamily including CD27, CD30, 4-1BB and OX40 have also been shown to transmit a costimulation signals to leukocytes [112, 113].”
BackgroundA cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857 · cited 2×
“The mechanisms of tumor escape from immune recognition/destruction are likely to be multifactorial, including down-regulation of MHC class I molecules [23–26], loss of tumor antigens [27, 28], defective death receptor signaling [29–33], lack of costimulation [34], and production of immunosuppressive cytokines [35] and…”
BackgroundCD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 1×
“AccumulationofGr1CD11bcells and their ability to inhibit the T-cell function has been reported in cancer patients [130].”
BackgroundSuppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific
Thornton, A. M., & Shevach, E. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.183 · Cited by 1,229 · cited 1×
“CD4CD25 T cells are known to be immunoregulatory and are important in immunological tolerance to self-antigens [39] and inhibition of T-cell proliferation [124].”
BackgroundFrumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133 · cited 1×
“Indoleamine 2,3-dioxygenase (IDO) is an enzyme ubiquitously distributed in mammalian tissues and cells converting tryptophan to N-formylkynurenine [41].”
Background
Cited by
Photodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., & Clay, T. M. (2008) · Blood · doi:10.1182/blood-2008-01-135319 · Cited by 300
Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome
Fogar, P., Sperti, C., Basso, D., Sanzari, M. C., Greco, E., Davoli, C., Navaglia, F., Zambon, C.-F., Pasquali, C., Venza, E., et al. (2006) · Pancreas · doi:10.1097/01.mpa.0000188305.90290.50 · Cited by 260
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 217
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
Kosmides, A. K., Sidhom, J.-W., Fraser, A., Bessell, C. A., & Schneck, J. P. (2017) · ACS Nano · doi:10.1021/acsnano.6b08152 · Cited by 170
Tgf-beta in the natural history of prostate cancer
Ahel, J. (2019) · Acta Clinica Croatica · doi:10.20471/acc.2019.58.01.17 · Cited by 30
Metadata
- Authors
- Ahmad, M., Rees, R., & Ali, S.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2004-06-10
- Volume
- 53
- Issue
- 10
- Pages
- 844-54
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1984301004
- Cited by
- 183
- References
- 117
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.